Alaunos Therapeutics Welcomes Nobel Prize-Winning Dr. Robert J. Hofmeister to its Board of Directors

Alaunos Therapeutics, Inc. (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company, is pleased to announce the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to its Board of Directors.

Dr. Hofmeister joins the Company at a pivotal time as it advances a clinical-stage pipeline of therapeutics for solid tumors, replacing Chris Bowden, MD, and bringing a wealth of experience and expertise to the team.

We are delighted to announce the addition of Robert to the Alaunos Board and express our sincere appreciation to Chris for his invaluable contributions during his tenure. Robert brings extensive knowledge in the discovery and development of engineered T-cell receptor therapies, as well as expertise in cellular immunology and translational science.

We are confident that his insights and experience will be instrumental in furthering our TCR-T Library Phase 1/2 trial and expanding our library of TCRs.

Dr. Hofmeister spent seven remarkable years at TCR2 Therapeutics, where he held the role of Chief Scientific Officer and was the first employee of the company. During his time at TCR2, he was instrumental in driving the development of its proprietary TRuC®-T cell platform and TC-210 program from concept to the first successful Investigational New Drug (IND) application.

His leadership and hard work also enabled the company to go public and secure growth capital. It’s no wonder that Dr. Hofmeister is now one of the leading figures in his current company.

Dr. Hofmeister is thrilled to be joining the Board of Directors at Alaunos, a pioneering biopharmaceutical company at the forefront of T-cell therapies. With the industry’s leading library of TCRs, a proprietary platform, and the first successful TCR-T clinical trial targeting driver mutations in solid tumors, Alaunos is making great strides in revolutionizing treatments for these diseases.

Dr. Hofmeister looks forward to collaborating with the executive team and Board members to continue to bring Alaunos’ mission to fruition.

Dr. Hofmeister is a biotech leader with a distinguished career in developing breakthrough treatments for cancer. His contributions to the field are remarkable, having been involved in the development of Bavencio (avelumab) and building the immuno-oncology platform at EMD Serono, as well as helping shape the development of Blincyto, the first FDA-approved bispecific antibody for the treatment of refractory ALL at Micromet AG (now Amgen Research Munich).

He holds a Ph.D. from the University of Regensburg and a postdoctoral fellowship from the National Cancer Institute. With his expertise and commitment to the field, Dr. Hofmeister is a beacon of hope in the fight against cancer.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics is revolutionizing solid cancer treatment with its cutting-edge T-cell receptor (TCR) cell therapy. Its clinical-stage TCR-T product candidates are being tested in a Phase 1/2 trial across six solid cancers, targeting driver mutations.

Powered by two proprietary platforms—its efficient non-viral Sleeping Beauty cell engineering platform, and its hunTR® discovery platform with a library of TCRs against high-frequency driver mutations—Alaunos is leading the way in TCR therapy, with a collaboration with the National Cancer Institute (NCI) and National Institutes of Health (NIH). Join us as we continue our mission to improve cancer outcomes and save lives.

Leave a Comment